HC Wainwright Has Negative Outlook for BLSM Q3 Earnings

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) – Stock analysts at HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for shares of BlossomHill Therapeutics in a note issued to investors on Thursday, September 24th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($0.93) per share for the quarter, down from their previous forecast of ($0.92). HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for BlossomHill Therapeutics’ current full-year earnings is ($5.54) per share. HC Wainwright also issued estimates for BlossomHill Therapeutics’ Q4 2026 earnings at ($0.92) EPS and FY2026 earnings at ($4.75) EPS.

Other equities analysts have also recently issued reports about the company. Leerink Partners raised their target price on BlossomHill Therapeutics from $36.00 to $40.00 and gave the company an “outperform” rating in a report on Monday, September 21st. JPMorgan Chase & Co. initiated coverage on shares of BlossomHill Therapeutics in a research report on Tuesday, September 1st. They set an “overweight” rating and a $28.00 price target on the stock. Lifesci Capital began coverage on shares of BlossomHill Therapeutics in a research note on Tuesday, September 1st. They issued an “outperform” rating and a $32.00 price objective for the company. Zacks Research raised shares of BlossomHill Therapeutics to a “hold” rating in a research note on Wednesday, September 2nd. Finally, Guggenheim raised their price target on shares of BlossomHill Therapeutics from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Monday, September 21st. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, BlossomHill Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $35.00.

BlossomHill Therapeutics Stock Performance

BLSM opened at $21.37 on Monday. BlossomHill Therapeutics has a 52 week low of $15.25 and a 52 week high of $27.99.

BlossomHill Therapeutics (NASDAQ:BLSM) last released its quarterly earnings results on Friday, September 18th. The company reported ($8.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($7.91).

Insider Transactions at BlossomHill Therapeutics

In other news, Director Orbimed Advisors Llc purchased 625,000 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was bought at an average price of $16.00 per share, for a total transaction of $10,000,000.00. Following the completion of the purchase, the director directly owned 2,714,279 shares of the company’s stock, valued at $43,428,464. The trade was a 29.91% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Carl Gordon purchased 625,000 shares of the stock in a transaction on Monday, August 10th. The shares were purchased at an average price of $16.00 per share, with a total value of $10,000,000.00. Following the acquisition, the director directly owned 2,714,279 shares in the company, valued at $43,428,464. This represents a 29.91% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 1,573,900 shares of company stock valued at $25,181,900 over the last quarter.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.